Marianne Uguen

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang et al. · Blood · 2019 · 384 citations · Full text

Medicine, Hematology, Pharmacology +6

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Guy Young, Robert F. Sidonio, Ri Liesner et al. · Blood · 2017 · 53 citations

Medicine, Pharmacokinetics, Pharmacology +9

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

Phillip Scheinberg, Diego V. Clé, Jin Seok Kim et al. · American Journal of Hematology · 2024 · 45 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia

Valentin Goede, Kirsten Fischer, Francesc Bosch et al. · Blood · 2015 · 43 citations

Medicine, Immunology, Oncology +13

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio et al. · Blood · 2018 · 37 citations

Medicine, Hematology, Pediatrics +17